Absci initiated with a Buy at Needham
Needham analyst Gil Blum initiated coverage of Absci (ABSI) with a Buy rating and $9 price target Absci “stands out from the pack due to its ...
The Business Journals6d
Absci shares jump as analyst lauds 'practical' AI drug company
Absci's ability to generate 'wet-lab data' gives it edge, Needham analsyst says. Shares in Vancouver-based AI drug creation company Absci soared on Wednesday after investment firm Needham & Co ...
AbSci’s Strategic Partnerships and Strong Financial Position Justify Buy Rating
Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on AbSci (ABSI – Research Report). The associated price ...